The Energy Code

They investigate whether diet soda and aspartame can trigger a mitochondrial crisis in ovaries and raise infertility risk. The conversation links oxidative stress, futile mitochondrial biogenesis, and an ATP threshold that matters for egg function. Practical angles include removing mitochondrial toxins and rebuilding cellular energy, plus a provocative look at possible transgenerational impacts.

They reframe aging as a mechanical feedback loop between mitochondria and telomeres. The conversation covers how mitochondrial ROS can chemically fray telomeres even without division. They dig into p53’s paradoxical role, TERT’s mitochondrial “moonlighting,” and the idea of senescent cells leaking citrate as a potential spreading signal. The practical focus is on protecting mitochondrial function to stop cascading damage.

They explore a 2025 paper showing urolithin B can trigger meniscal regeneration in a mouse model. The conversation covers how this gut-derived metabolite suppresses inflammatory and tissue-degrading signals. They describe how urolithin B boosts cartilage-building programs like SOX9, collagen, and VEGF. They also explain why diet may not provide enough for many people and the case for direct delivery.

Nico Martens, subtle-energy practitioner and BioGeometry coach, shows how shapes and vibration shape health. He demos 'The Card' and discusses harmonizing spaces, mitigating EMF stress, and tuning food and water. Short, surprising stories and practical tools paint a picture of an unseen layer that influences biological vitality.

A deep look at traumatic optic neuropathy and how blunt head injury can silently steal vision. A 2025 rat study tests methylene blue as immediate metabolic rescue to preserve retinal signaling and ganglion cells. The conversation covers optic canal anatomy, secondary degeneration timing, mitochondrial electron bypass mechanisms, and translational implications for acute vision-saving interventions.

A deep dive into mitochondria as a semi‑independent ‘second genome’ with its own epigenetic software. They unpack how tumors rewire mitochondrial methylation, packaging, and noncoding RNAs to fuel growth or induce dormancy. The conversation highlights mitochondrial–nuclear cross‑talk and explores mitochondrial RNAs and methylation as potential biomarkers and therapeutic targets.

They unpack a piglet study showing a common grain mold toxin collapses the gut’s mucus and tight junctions. They explore how damaged mitochondria and lost ATP drive apoptosis and tissue breakdown. They highlight taurine’s surprising role in rebooting mitochondrial function and reactivating the PGC‑1 → NRF1/2 repair axis.

They explore using a light-activated dye to wipe out antibiotic-resistant bacteria in lab samples from pediatric abdominal infections. They describe how methylene blue plus red light generates reactive oxygen to kill microbes. They discuss striking kill rates for E. coli and Streptococcus, more variable effects on Pseudomonas, and ideas for surgical, localized light delivery. They note key limitations and next research steps.

They explain what Urolithin A is and why gut bacteria make its effects hit-or-miss. They cover why supplements bypass that variability and produce consistent blood levels. They discuss dose-dependent anti-inflammatory signals and mitochondrial/autophagy gene changes. They highlight some selective strength and endurance gains while noting many common biomarkers did not change in short trials.

Welcome to the first Energy Code Deep Dive—daily research reviews translated into real life. Dr. Mike Belkowski and co-host Don Bailey break down a brand-new (Jan 3, 2026) pilot study on transcranial photobiomodulation (tPBM) for chemobrain (cancer-related cognitive impairment).   We define what chemobrain actually feels like, why there aren’t many proven treatments, and why researchers are exploring 810nm brain-directed light + an intranasal component to support mitochondrial energy (cytochrome c oxidase/ATP), inflammation balance, blood flow, and repair signaling.   Then we walk through the real-world clinical cohort (31 women), the protocol (weekly sessions, ~20 minutes, 10+ sessions), and the eye-opening outcomes: 29/31 improved, average cognitive scores rose dramatically, and a meaningful percentage normalized. We also keep it honest—small sample, retrospective design, no control group—so you know what’s promising now and what still needs randomized trials. - Article Discussed in Episode: Transcranial photobiomodulation for the treatment of chemobrain: new perspectives from a pilot study - Key Quotes From Dr. Mike: “It’s like your brain’s running 30 browser tabs and somebody started a video call in the background.” “Think of it like giving your brain cells a more efficient ‘charge cycle,’ not by caffeine, but by improving cellular energy production.” “This is why device specs aren’t nerd trivia. They’re the difference between a protocol and a placebo.” “This pilot study suggests that transcranial photobiomodulation may meaningfully improve chemobrain symptoms… but we still need larger controlled trials.” - Key points Chemobrain is real: attention, processing speed, verbal fluency, executive function — often lingering for years and impacting daily life. The study reviewed a Jan 3, 2026 pilot exploring tPBM as a potential supportive treatment when proven options are limited. Mechanism focus: light targets mitochondrial function (cytochrome c oxidase → ATP), with downstream effects on inflammation, blood flow, and repair signaling. Cohort: 31 women, average age ~52, post-chemo cognitive impairment; cognition tracked via FACT-Cog. Protocol: 810nm transcranial + intranasal, ~20 min/session, weekly, 10+ sessions; some also used whole-body PBM. Why 810nm: penetration matters; modeling suggests near-optimal depth to reach cortical targets; intranasal may help access harder-to-reach regions. Results were striking: average score improved from ~63 to ~101; 29/31 improved; ~29% normalized into typical range. Limitations & takeaway: retrospective + no control group (can’t rule out time/placebo), but the effect size supports moving toward larger randomized trials and reinforces that parameters/device specs matter. - Episode timeline  00:00 – Welcome to the first Energy Code Deep Dive + Don’s role as the “question-asker” 01:30 – What is chemobrain (symptoms + what it feels like day-to-day) 04:00 – Why treatment options are limited (the “brutal part”) 05:30 – What transcranial photobiomodulation is (plain-English translation) 07:30 – Biology: cytochrome c oxidase, ATP, inflammation, blood flow, repair signaling 10:00 – Study design + who they studied (31 women, France, post-chemo, FACT-Cog) 12:30 – Real-life impacts (reading, admin work, conversations, driving, fatigue, sleep) 14:30 – Protocol details (810nm, intranasal, weekly 20 min, 10+ sessions, some whole-body) 17:00 – Why 810nm + why intranasal (penetration + access) 19:00 – Results (63 → 101, 29/31 improved, ~29% normalized, QoL changes) 21:30 – Mood/anxiety/depression findings + interpretation 23:00 – Mechanisms: chemo injury pathways vs PBM supportive pathways 25:30 – Limitations (small sample, retrospective, no control, can’t split brain vs whole-body) 27:30 – Safety notes + “what do I do with this?” (talk to clinician; parameters matter) 29:00 – One-sentence takeaway + close (“Protect your energy / mitochondria”) - Dr. Mike's #1 recommendations:   Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com   -   Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight: Website Instagram YouTube Facebook